In December, PersonGen was included in the list of " 2023 Deloitte China Life Sciences & Healthcare (LSHC) Rising Star ".
In December, PersonGen.Anke Cellular Therapeutics Co., Ltd.won the honorary title of " Gazelle Cultivation Enterprise " and " Advanced Technology Enterprise " in Hefei High-tech Zone in 2023.
In December, PersonGen was awarded the key project for technology development of the " 2023 National Biological Medicine Technology Innovation Center ".
In November, PersonGen.Anke Cellular Therapeutics Co., Ltd. joined Anhui Pharmaceutical Industry Association.
In November, PersonGen.Anke Cellular Therapeutics Co., Ltd. was granted the " 2023 Hefei Enterprise Technology Center ".
In October, PersonGen won the " Winning Project Award " in the 2nd Yangtze River Delta G60 Science and Innovation Corridor Technology and Industry Innovation Competition".
In October, Dr. Wang Min, Vice President of PersonGen.Anke, joined the Hefei High-tech Zone Women Entrepreneurs Association.
In September, PersonGen BioTherapeutics (Suzhou) Co., Ltd. was approved as the first batch of nursery enterprises in 2023.
In September, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " 2023 Pharmaceutical Company Digital Intelligence Transformation Intelligent Production Leadership Award ".
In August, Dr. Wang Min, Vice president of PersonGen.Anke, won the 2023 BPD " Young Craftsman Award of Biological Medicine ".
In July, Dr. Wang Min, Vice President of PersonGen, was selected as one of the U40-Young Elites.
In June, Dr. Lin Yang, founder of PersonGen, won the " BioCon Awards - the Influence Star of Biotech Industry in 2023 ".
In April, the B7-H3 CAR T cell therapy product " TAA06 injection " for the treatment of relapsed/refractory neuroblastoma completed the first patient dosing.
In April, PersonGen BioTherapeutics (Suzhou) Co., Ltd. won the " CGT Industry Star - 2023 Most Innovative Award ".
In March, the opening ceremony of the intelligent and fully-automated cell production base of PersonGen and the "PersonGen Cell Therapy Development Innovation Summit " were grandly held in Hefei on March 28th,2023.
In March, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " Winning Project Award " in the finals of the " 2022 National Disruptive Technology Innovation Competition ".
In March, PersonGen BioTherapeutics (Suzhou) Co., Ltd. won the " Excellent Project Award " in the finals of the " 2022 National Disruptive Technology Innovation Competition ".
In March, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " Excellence award " in the final of " The 3rd Yangtze River Delta Translational Medicine (medical device direction) Innovation and Entrepreneurship Competition ".
In March, PersonGen BioTherapeutics (Suzhou) Co., Ltd. was awarded " 2022 TOP 100 Innovative Breakthrough Enterprises ".
In February, PersonGen.Anke Cellular Therapeutics Co., Ltd. became one of the governing unit of Hefei Biomedical Industry Association.
In December, for " TAA06 Injection " , one CAR-T cell therapy product targeting B7-H3, independently developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd., the Phase I clinical trial was officially launched in Tianjin Medical University Cancer Institute & Hospital for treatment of " relapsed/refractory neuroblastoma ".
In December, Exclusive Interview | Dr. Yang Lin: Cell Drug Entrepreneurship is a " Game " for only a few People.
In December, | PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " Second Prize " in " The 2nd Anhui Province Life and Health Industry Innovation Competition ".
In December, | PersonGen won the " Winning Project Award " in " The 2nd National Disruptive Technology Innovation Competition ".
In November, Xu Tao, academician of the Chinese Academy of Sciences, visited biopharmaceutical key enterprise: PersonGen.Anke Cellular Therapeutics Co., Ltd.
In November, Dr. Yang Lin, Chairman of PersonGen, was listed in the " 2022 China CGT Annual Influential Enterprise Leader ".
In September, ESMO Congress 2022 | PersonGen announced the research results of CAR-T combined with radiotherapy pretreatment for solid tumors.
In September, Dr. Yin Wu, one of the world's top authoritative experts on γδT cell research, became the scientific and medical advisor of PersonGen.
In September, Dr. Yang Lin, founder of PersonGen, accepted an exclusive interview from Hong Kong Commercial Daily.
In September, PersonGen was included in the list of " Top 100 Pharmaceutical Innovative Enterprises of 2022 in China ".
In September, Dr. Yang Lin, founder of PersonGen, won the BioCon Awards for Excellence in Biotechnology and was invited to give a keynote speech.
In September, PersonGen.Anke Cellular Therapeutics Co., Ltd. joined hands with the University of Science and Technology of China and won the special promotion of Anhui Science and Technology News.
In August, Exclusive Interview | The " Unusual " Dr.Yang Lin, Run an Atypical CAR-T Company for 12 Years.
In August, Exclusive Interview | Dr.Yang Lin: IND Approval is No Longer a Bright Spot, Cell Therapy Industry is on the Eve of a Greater Breakthrough in China.
In July, the third " TONACEA Cell and Gene Therapy Club Council " was held, and Dr. Yang Lin was elected as the executive director.
In July, Interview | PersonGen Yanglin: Current Status and Future of CAR-T Cells Combined with Oncolytic Viruses in the Treatment of Solid Tumors.
In July, the world's first clinical trial of CAR-T therapy (TAA06 injection, targeting B7-H3) for pediatric r/r neuroblastoma was approved by the National Medical Products Administration of China.
In June, PersonGen has built a fully automated CAR-T cell industrialization base in Hefei High-tech Zone.
In May, PersonGen presided over the Development of Major Special Projects of Science and Technology in Anhui Province.
In April, PersonGen announced that the first patient in the Phase I clinical trial of PA3-17 injection had completed the infusion.
In April, PersonGen announced the acceptance of IND Application of B7-H3 CAR-T (TAA06 Injection) by CDE.
In March, TAA06 was granted ODD and RPD for the treatment of neuroblastoma by U.S. FDA.
In January, PersonGen has completed the B Round of Financing led by China Kim Kaide(Xiamen)Innovative Biomedical Equity Investment Fund Partnership(L.P.) and Nanjing Huatai Guoxin Medical Investment Partnership (Limited Partnership) , and co-invested by PANYI(SUZHOU) Capital Management Co.Ltd and Jiangsu Huatong Private Equity Fund Management Co., Ltd.
In December, PersonGen won the " Excellent Project Award " in the 2021 National Disruptive Technology Innovation Competition.
In November, won the designation of " 2021 Hefei High-Growth Seed Enterprise ".
In November, PA3-17 injection was granted ODD by U.S. FDA.
In November, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the " 2021 Hefei High-tech Zone Eagle Enterprise ".
In October, PersonGen won the " Annual Award of 2021 China Bioinnovative Drugs with the Most Growth Potential ".
In August, PersonGen announced the IND application of PA3-17 injection, a globally first autologous CD7-CAR-T cell product, was approved in China.
In June, Dr. Yang Lin was awarded the " Top 10 Drug Innovation Scientists of 2020 ".
In May, PersonGen has completed A Round of Financing led by bioVenture Capital, followed by Puen Guoxin Equity Investment and Sangel Capital.
In April, PersonGen invested and established PersonGen BioPharmaceutical (Shijiazhuang) Co., Ltd.
In March, PersonGen won " the Second Prize of Anhui Province Science and Technology Award ".
In March, after the completion of a major internal restructuring, PersonGen Anke became a wholly-owned subsidiary of PersonGen Group.
In December, PersonGen won the Young Eagle Enterprise Designation of Hefei High-tech Zone in 2020.
In December, Development of the Allogeneic UCAR-γδT Cell Platform.
In August, IND applications for multiple first-in-class CAR-T cell products.
In December, PersonGen won the " Deep Cultivation Award of Cell Therapy Enterprise ".
In December, PersonGen was awarded the "Listed Nursery Enterprise".
In December, PersonGen has built a Clinical-Grade Lentivirus Suspension Preparation Technology Platform.
In December, PersonGen announced the Clearance of IND Application of CD19-CAR-T by CDE.
In November, PersonGen won the National High-Tech Enterprise.
In September, PersonGen's autologous CD7-CAR-T achieved a major breakthrough.
In June, PersonGen's CD7-CAR-NK achieved a major progress.
In April, Dr. Lin YANG was awarded the "Leading Entrepreneurial Talent" in Hefei City.
In March, PersonGen participated in the cooperative development of key research and development projects in Anhui Province.
In March, Dr. Yang Lin won the " Award of Excellent Paper ".
In February, PersonGen has achieved major clinical progress in CD19-CAR-T and BCMA-CAR-T cell products.
In December, PersonGen participated in the cooperative research and development of major science and technology special projects in Anhui Province.
In October, Dr. Lin YANG was awarded the title of "Technical Leader in Anhui Province".
In June, PersonGen built "Off-the-shelf γδT Cell Preparation Platform".
In February, PersonGen was awarded as the " 2017 Outstanding Enterprise of Hefei High-Tech Zone " and " Talent Attraction Award ".
In February, PersonGen won the designation of "Hefei Luzhou Industrial Innovation Team".
In January, PersonGen has built China's first fully automated CAR-T Cell Preparation Platform.
In November, PersonGen.Anke Cellular Therapeutics Co., Ltd. won the honour of NO.1 in " Innovation Resonating in China" of Anhui Province" , " Luzhou Industrial Innovation Team " and " Hefei Entrepreneurial Leading Talents ".
In December, PersonGen won " The Second Prize" in "China Innovation and Entrepreneurship Competition ".
In November, PersonGen won " The First Prize " in "Anhui Province Innovation and Entrepreneurship Competition of Innovation Resonating in China".
In October, PersonGen developed a Semi-automatic Modular CAR-T Preparation Process.
In September, PersonGen developed a Clinical-Grade Plasmids and Lentiviruses Processes.
In December, PersonGen invested 100 million yuan to establish an industrialization base (PersonGen Anke Cell Technology Co., LTD.) in Hefei High-Tech Zone.
In November, PersonGen undertook the research and development of sub-projects of National Key Research and Development Programs.
In November, PersonGen won the designation of National High-Tech Enterprise.
In September, PersonGen was rated as a High-Level Talent Team of " Six Talent Peak ".
In June, the Structure, Function and Activity Verification Platform of CAR was successfully built.
In November, PersonGen received capital investment from Anhui Anke Biotechnology (Group) Co., Ltd.
In November, PersonGen launched the world's first clinical trial of a MUC1-CAR-T cell products for solid tumors.
In July, PersonGen won the Advanced Technology Service Enterprise.
In March, PersonGen launched the world's first clinical trial of a multi-target CAR-NK cell product.
In November, PersonGen successfully developed a PD-1 blocking antibody.
In June, PersonGen successfully developed a CD7 Nanobody.
In March, PersonGen successfully built a NK cell preparation platform.
In December, PersonGen was awarded ISO9001: 2008 Quality Management System Certification.
In October, Dr. Lin YANG was awarded the High-Level Entrepreneurship Talent of Jiangsu Province.
In June, PersonGen built a Bi-Specific CAR-T Technology Platform.
In May, PersonGen was approved to set up a Enterprise Postdoctoral Incubation Station in Suzhou Industrial Park.
In December, PersonGen has successfully built a Nano-Antibody Screening Platform.
In October, PersonGen was approved to establish Suzhou Engineering Technology Research Center for Tumor Immunodiagnosis and Treatment.
In August, PersonGen obtained Angel Round Investment from Zhongxin Venture Capital.
In July, PersonGen was awarded the title of Private Technology Enterprise in Jiangsu Province.
In July, Dr. Lin YANG was awarded the Gusu Leading Talent of Innovation and Entrepreneurship.
In March, PersonGen built the 2nd and 3rd generation CAR-T Technology Platform.
In December, PersonGen built a technology platform for in vitro preparation of T cells.
In October, PersonGen was awarded the title of Jiangsu Provincial Innovation Team Member.
In December, Dr. Lin YANG was awarded the Leading Talent in Science and Technology of Suzhou Industrial Park.
In May, the Company was registered and established in Suzhou Industrial Park.